{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Von+Willebrands+Disease",
    "query": {
      "condition": "Von Willebrands Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 45,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Von+Willebrands+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-21T17:46:14.916Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02973087",
      "title": "rVWF IN PROPHYLAXIS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease"
      ],
      "interventions": [
        {
          "name": "von Willebrand factor (Recombinant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Antihemophilic Factor (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2017-11-16",
      "completion_date": "2020-07-06",
      "has_results": true,
      "last_update_posted_date": "2021-08-06",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 8,
      "location_summary": "Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Aurora",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973087"
    },
    {
      "nct_id": "NCT03621020",
      "title": "Clinical Performance Evaluation of T-TAS 01 PL Chip",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Platelet Dysfunction",
        "Von Willebrand Diseases",
        "Healthy",
        "Congenital Platelets Abnormality"
      ],
      "interventions": [
        {
          "name": "T-TAS 01 PL Chip",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "PFA-100 Col/Epi and Col/ADP",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Hikari Dx, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 307,
      "start_date": "2018-09-01",
      "completion_date": "2020-02-14",
      "has_results": false,
      "last_update_posted_date": "2020-02-18",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03621020"
    },
    {
      "nct_id": "NCT00524342",
      "title": "IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Von Willebrand Disease"
      ],
      "interventions": [
        {
          "name": "Oprelvekin, Interleukin 11, IL-11",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret Ragni",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2008-01",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00524342"
    },
    {
      "nct_id": "NCT04770935",
      "title": "To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Von Willebrand's Disease (VWD)"
      ],
      "interventions": [
        {
          "name": "efanesoctocog alfa (BIVV001)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-05-03",
      "completion_date": "2022-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770935"
    },
    {
      "nct_id": "NCT03879135",
      "title": "A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease (VWD)"
      ],
      "interventions": [
        {
          "name": "rVWF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rFVIII",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2019-04-01",
      "completion_date": "2025-01-30",
      "has_results": true,
      "last_update_posted_date": "2025-09-03",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03879135"
    },
    {
      "nct_id": "NCT06610201",
      "title": "A Study of Bleeding and Treatment in Participants With Von Willebrand Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Willebrand Disease (VWD)",
        "Von Willebrand Disease (VWD), Type 1",
        "Von Willebrand Disease (VWD), Type 2",
        "Von Willebrand Disease (VWD), Type 3",
        "Von Willebrand Disease, Type 2A",
        "Von Willebrand Disease, Type 2M",
        "Von Willebrand Disease, Type 2N"
      ],
      "interventions": [
        {
          "name": "Clinical outcomes of patients with VWD, Type 1",
          "type": "OTHER"
        },
        {
          "name": "Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Hemab ApS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-08-30",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06610201"
    },
    {
      "nct_id": "NCT01365546",
      "title": "Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prevent Bleeding in Major Surgery"
      ],
      "interventions": [
        {
          "name": "human VWF/FVIII concentrate",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-06",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2015-03-09",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Chapel Hill, North Carolina • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365546"
    },
    {
      "nct_id": "NCT02466789",
      "title": "Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Willebrands Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Jonathan Roberts",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2015-07",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2022-08-10",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 1,
      "location_summary": "Peoria, Illinois",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02466789"
    },
    {
      "nct_id": "NCT06883240",
      "title": "An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Willebrand Disease, Type 3"
      ],
      "interventions": [
        {
          "name": "Von Willebrand Factor Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Von Willebrand Factor Concentrates and Factor VIII Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Factor VIII Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Activated Factor VII",
          "type": "DRUG"
        },
        {
          "name": "Activated Prothrombin Complex Concentrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2025-04-29",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883240"
    },
    {
      "nct_id": "NCT01410227",
      "title": "Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease"
      ],
      "interventions": [
        {
          "name": "Recombinant von Willebrand factor (rVWF)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Recombinant factor VIIII (rFVIII)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 49,
      "start_date": "2011-11-01",
      "completion_date": "2014-02-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-07-21T17:46:14.916Z",
      "location_count": 10,
      "location_summary": "Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01410227"
    }
  ]
}